Please wait...

You selected inventions in category Life Sciences

  • 3D-Phone Increaser  - Turn your Smartphone into a 3D Monitor - for all VIDEOS, FOTOS and GAMES !3D-Phone Increaser - Turn your Smartphone into a...
      Preview
      Description

      Yes, it's possible! Turn your smartphone into a 3D monitor.

      Handling is easy open the 3D-Phone Increaser, insert smartphone and adjust focus. PRESS PLAY that was about everything, you sit back and enjoy fantastic 3D experience wherever you want it.

      Simple technology and a fantastic result. On the annoying 3D glasses can be dispensed through the 3D Phone Increaser. The results are also better than of other current 3D techniques. The picture has more depth, is sharper and there are no overlapping distorted images. In addition, no special software or format is needed, the technique works for any video, image or game.

      Full details Contact close
    • A Formulation for treating LeishmaniasisA Formulation for treating Leishmaniasis
        Preview
        Description

        The technology is in form of a formulation that is effective in treating intracellular protozoan parasitic infections (especially Leishmaniasis) and overcoming the associated complications. The technology provides a sterol enriched mixed lamellarity amphotericin intercalating liposomes for targeted delivery of liposomal amphotericin B thereby reducing toxicities of amphotericin B. The liposomal formulation is sonicated before administration to increase the plasma half-life of the liposomal drug for facilitating better bio-distribution in the body. The formulation is sugar free and thus can be freely use by diabetics. The technology has been tested on the mice for tolerance study

        Full details Contact close
      • A herbal pesticideA herbal pesticide
          Preview
          Description

          The present technology provides a sprayable biopesticidal composition comprising Photorhabdus luminescens for controlling and eradicating various agricultural pests. It is for the first time that the insecticidal activity of P. luminescens is used without its symbiotic carrier nematode. In the present technology the actively growing cells of P. luminescens are encapsulated in sodium alginate beads and examined for their ability to infect insect hosts. Several laboratory and field testing programme were carried out to evaluate and assess the product. Elaborative and extensive field trials were conducted to study the efficacy of the product on the serious pest of sugarcane. The results obtained from these experiments have given a clear indication that the product is very effective and is novel based on the bacterium Photorhabdus luminescence and the plant, bacterial and insect chitinase purified to greatest extent and stabilized for longer shelf life.

          Full details Contact close
        • A kit to diagnose Heart diseaseA kit to diagnose Heart disease
            Preview
            Description

            The proposed technology suggests a heart disease diagnostics kit that uses multifractal analysis tests to produce an integrated, noninvasive diagnostic/prognostic approach for diagnosis of heart disease, prognostication, prediction of risk of sudden death, and prediction of response to therapy. Useful results from these tests can be made available in 15 minutes or less to several hours. A multifractal version of the ST alpha scaling coefficient and a multifractal version of the LT alpha offer additional useful information about cardiac disease. Researchers have also refined preexisting multifractal analytic methods to eliminate the confounding effect of skipped/abnormal/ectopic beats, frequently found in the general population and patients with cardiac disease.

            Full details Contact close
          • A Lipid-based Drug for Treating CancerA Lipid-based Drug for Treating Cancer
              Preview
              Description

              The technology is in form of a “Lipid based drug” which is aimed at treating cancer by occluding the blood supply to the tumor region. The said drug when injected intra-tumorally cut off the blood supply to the tumor, causing it to basically starve and die because of a lack of blood, without leaving any side-effect on the patient body. This is for the first time ever a lipid-based drug is developed for cancer. The molecule developed is a naturally occurring lipid present in the body, is non –toxic, and has both direct and selective tumoricidal and anti-angiogenic actions.
              The angiography study performed on five patients who have been administered this drug clearly highlights its highly selective mode of action. The administered drug selectively occludes tumor-feeding vessels without having any significant side-effects on the adjoining tissues.
              The methods of administration of this drug:
              (a) To locate an artery which carries major blood supply to the neoplastic region and which is proximal to the neoplastic region
              (b) Intra-arterially injection of therapeutically effective amount of “Lipid-based drug” into the located artery

              Full details Contact close
            • A Modular Screwless Furniture Assembly Indian Patent No 226078A Modular Screwless Furniture Assembly Indian...
                Preview
                Description

                OUR CONCEPT IS UNIQUE , IT IS MULTIPURPOSE, IT CAN BE USED IN TILING FORM AND INSERTING ALSO, IT CAN BE USED FOR WALL PANELING, FULL HEIGHT PARTITIONS,THE RANGES OF PRODUCT AVAILABLE IN THE MARKET ARE MUCH INFERIOR TO THE PRODUCT INVENTED BY US AND ARE ALSO TOO COSTLY THOUGH OUR ENTIRE FRAME WORK (SKELETON) IS OF ALUMINIUM. WE CAN OFFER OUR PRODUCT IN THE OPEN MARKET AT MUCH LESSER PRICE THEN THE PRESENT RATES PREVAILING IN THE MARKET AND IN THAT EVENT STILL WE CAN HAVE THE HANDSOME PROFITS. THIS MODULAR SCREW LESS FURNITURE ASSEMBLY CAN BE DISMENTLED AT ANY POINT OF TIME WITH OUT CHANGING ITS QUALITY, LOOK AND CAN BE TRANSPORTED AT ANY OTHER PLACE RE-ERRECTION AND RE-USE, AND THIS CAN BE DONE ANY NUMBER OF TIME, A SYSTEM WHICH MANIPULATE YOUR CREATIVE MIND.


                contact no:

                9820854298 / 62.
                himmat /mahendra.
                works: 6416 5456
                fax: 2896 3703

                email id:
                uniquekreation_kmm@yahoo.co.in

                web:
                www.uniquekreationindia.com


                for ready reference you can also visit on

                http://www.officemodularfurnitures.com/
                www.kmmistry.com

                Full details Contact close
              • A NEW DRUG FOR THE PREVENTION AND TREATMENT OF HERPES SIMPLEX VIRUS HSV-1A NEW DRUG FOR THE PREVENTION AND TREATMENT OF...
                  Preview
                  Description

                  Herpes simplex virus 1 (HSV-1), is one of the most commonly encountered pathogens in humans. The most recent statistics indicate that approximately 50-90% of the world population is HSV-1 seropositive. The most common primary infections are cold sores occurring mainly on the face (especially the skin, tongue and lips). However, infection with HSV-1 may also lead to severe diseases such as inflammation of the eye or encephalitis. These diseases are characterized by severe course and may cause permanent adverse health effects (e.g. blindness), and even death.

                  Currently, there are several antiviral drugs, which are active against pathogens belonging to the Herpesviridae family. These drugs reduce the frequency and severity of relapses and also alleviate bothersome symptoms during the primary infection. Although they are usually only effective for the initial infection, they do not eliminate a virus in a latent state and thus do not protect a person before re-emergence of symptoms. There has also been increasing emergence of drug resistant viral strains. Thus, there is a need to find a new approach to developing effective treatment of HSV-1 infection. The new invention of the Jagiellonian University, which is the subject of the proposed offer, discloses a new drug for treatment of herpes simplex virus (HSV-1) infection.

                  The main advantages of the offered drug are:
                   confirmed ability to efficient bind of herpes simplex virus (HSV-1)
                  and inhibit its replication in vitro,
                   low-toxicity of the drug in vitro,
                   the possibility to apply as an ointment or solution administrated either topically to the skin or eye, orally, intraperitoneally or intravenously.

                  The offered invention is subject of a patent application. Further research
                  and development are conducted at the Faculty of Chemistry and Faculty of Biochemistry, Biophysics and Biotechnology of the Jagiellonian University. Currently, the Centre for Technology Transfer CITTRU is looking for partners interested in the development of the invention and its commercial application.

                  More information:
                  PhD Klaudia Polakowska – Technology Transfer Officer
                  phone. +48 12 663 3832, +48 519 329 129, klaudia.polakowska@uj.edu.pl

                  Full details Contact close
                • A new drug for the prevention and treatment of human influenza A virus IAV human metapneumovirus hMPV and human rhinoviruses HRVA new drug for the prevention and treatment of...
                    Preview
                    Description

                    Potential drug: a modified polyallylamine derivative

                    Application: prevention and treatment of human influenza A virus (IAV), human metapneumovirus (hMPV) and human rhinoviruses (HRV)

                    Influenza is an acute infectious disease caused by viruses belonging to the Orthomyxoviridae family, and classified into three types: A, B and C. This classification is based on antigenic differences between the major virion proteins, e.g. M protein and nucleoprotein NP. These types differ in terms of epidemiological properties.

                    Influenza A virus (IAV) causes acute and chronic respiratory infections. It is a major respiratory pathogen of humans and animals. A period of frequent influenza infections occurs each winter (seasonal flu, the highest incidence occurring
                    in January/February). Only type A influenza virus causes epidemics and pandemics because of antigenic shift that is multiple changes in the various genome segments resulting from reassortment of different strains of the virus.

                    According to the World Health Organization (WHO) infections with influenza
                    and influenza-like viruses occur globally with an annual attack rate estimated at 5%-10% in adults and 20%-30% in children. Worldwide, these annual epidemics are estimated to result in about 3 to 5 million cases of severe illness, and about 250 000 to 500 000 deaths. The most severe infections develop in children under two years of age, in the elderly aged 65 or older and in those with compromised immunity. WHO recommends vaccination against the influenza virus as the most effective way to prevent infections. On the other hand, because of a large variability of the virus, the difficulty in obtaining sufficient number of vaccines before the epidemic wave, and not always satisfactory efficacy of the vaccine and anti – influenza drugs, the disease still represents an important medical and epidemiological problem. Therefore, new effective drugs for the anti-influenza treatment are needed.

                    The new invention of the Jagiellonian University, which is the subject
                    of the proposed offer, discloses a new drug for the treatment of human A virus (IAV) infection.

                    Human metapneumovirus (hMPV) was identified in 2001, however, it was proved that infections with this pathogen have occurred in the human population for
                    at least 50 years now. It is the only known Pneumovirus which infects humans and causes both upper and lower respiratory tract infections. Respiratory infections caused by hMPV have been reported in patients of every age and gender,
                    but children under 5 years are most likely to be susceptible to infections caused
                    by hMPV. The clinical manifestations of hMPV disease are flu-like symptoms such
                    as runny nose, cough, sore throat and high fever. The virus is widespread, and is found on all continents. Late winter and early spring is the epidemic peak of hMPV infections. More serious symptoms, including severe lower respiratory tract infections, are found mainly in young children and infants under 5 years
                    of age, elderly individuals above 60 years of age, and immunocompromised patients, whereas immunocompetent adults present mostly flu-like illnesses or cold symptoms.
                    So far, no other drug has been approved for inhibition and prevention
                    of infections caused by hMPV. By 2012, the only drugs with broad spectrum
                    of activity (such as ribavirin and immunoglobulins) have been used to treat very acute, severe hMPV infections of patients after lung transplantation. The new invention of the Jagiellonian University, which is the subject of the proposed offer, discloses a new drug for treatment of human metapneumovirus (hMPV) infection.

                    The human rhinovirus (HRV) belongs to the smallest known viruses (their diameter does not exceed 30 nm). During the year, particularly in winter and spring, it causes infections of the upper respiratory tract with humans, appearing as the common cold. Rhinoviruses also cause otitis media, sinusitis and inflammations of the lower respiratory tract, including bronchi

                    Full details Contact close